Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
Go back to Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation| Edwards Lifesciences (NYSE: EW) | Delayed: 86.95 +1.07 (1.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $85.88 | 52 Week High | $166.87 | |||
| Open | $86.19 | 52 Week Low | $72.20 | |||
| Day High | $87.22 | P/E | 25.28 | |||
| Day Low | $85.46 | EPS | $3.44 | |||
| Volume | 4,867,821 | |||||
